Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Tara L. Peters"'
Publikováno v:
Thoracic Cancer, Vol 14, Iss 33, Pp 3259-3265 (2023)
Abstract Background The vast majority of patients with ROS1 positive non‐small cell lung cancer (NSCLC) derive clinical benefit from currently approved ROS1 therapies, including crizotinib and entrectinib. However, a small proportion of patients tr
Externí odkaz:
https://doaj.org/article/b4a49be5552c4d6ea20d58cdd6f1cf4d
Autor:
Jonathan H. Schatz, Eli Chapman, Abimael D. Rodríguez, Graham Packham, Cyril H. Benes, Francisco Vega, Patricia Greninger, Gillian Paine-Murrieta, Andrew J. Ambrose, Christopher J. Zerio, Praechompoo Pongtornpipat, Amit D. Amin, Lingxiao Li, Luis A. Amador, Carlos Jiménez-Romero, Elizabeth Lemm, Sarah Wilmore, Alison M. Yeomans, Joseph Tillotson, Tara L. Peters
Figure S1. Elatol was submitted to a 96-member kinome screen to evaluate specificity. Figure S2. A) Michaelis-Menten curves of eIF4A1 wild type (blue), K82R (red), and K238E (green). Michaelis- Menten constants for eIF4A1 wild type and mutants in tab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43b0c08aa1ad75e37b8b895a22244a71
https://doi.org/10.1158/1078-0432.22469778.v1
https://doi.org/10.1158/1078-0432.22469778.v1
Autor:
Jonathan H. Schatz, Eli Chapman, Abimael D. Rodríguez, Graham Packham, Cyril H. Benes, Francisco Vega, Patricia Greninger, Gillian Paine-Murrieta, Andrew J. Ambrose, Christopher J. Zerio, Praechompoo Pongtornpipat, Amit D. Amin, Lingxiao Li, Luis A. Amador, Carlos Jiménez-Romero, Elizabeth Lemm, Sarah Wilmore, Alison M. Yeomans, Joseph Tillotson, Tara L. Peters
Purpose: The DEAD-box RNA helicase eIF4A1 carries out the key enzymatic step of cap-dependent translation initiation and is a well-established target for cancer therapy, but no drug against it has entered evaluation in patients. We identified and cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e0a4100a7388fdcb4d088138f676666
https://doi.org/10.1158/1078-0432.c.6527340
https://doi.org/10.1158/1078-0432.c.6527340
Autor:
Jonathan H. Schatz, Soham D. Puvvada, Yves A. Lussier, Lisa M. Rimsza, Jonathan Adkins, Lori Cuyugan, Tara L. Peters, Edgar O. Tapia, Matthew J. Groysman, Praechompoo Pongtornpipat, Winnie S. Liang, Soumya S. Rajan, Amit Dipak Amin
Supplementary Tables S1-S2. Relative IC50's of ALK+ and ALK- ALCL cell lines to the ALK tyrosine kinase inhibitors crizotinib and ceritinib (S1); ALK Kinase-Domain Sequencing Results (S2).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1f3399ead6ef9ebe83b0200a630176b
https://doi.org/10.1158/0008-5472.22405214.v1
https://doi.org/10.1158/0008-5472.22405214.v1
Autor:
Jonathan H. Schatz, Soham D. Puvvada, Yves A. Lussier, Lisa M. Rimsza, Jonathan Adkins, Lori Cuyugan, Tara L. Peters, Edgar O. Tapia, Matthew J. Groysman, Praechompoo Pongtornpipat, Winnie S. Liang, Soumya S. Rajan, Amit Dipak Amin
Supplementary Figures S1-S5. Timelines for acquired resistance and resensitization (S1); Assessment of copy number changes in additional subclones (S2); RS lines behave like original parent cells with return of ALK expression to baseline (S3); Resele
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c09c6e35d3b74b7a4d3f9c5b3fc1981
https://doi.org/10.1158/0008-5472.22405220
https://doi.org/10.1158/0008-5472.22405220
Autor:
Jonathan H. Schatz, Soham D. Puvvada, Yves A. Lussier, Lisa M. Rimsza, Jonathan Adkins, Lori Cuyugan, Tara L. Peters, Edgar O. Tapia, Matthew J. Groysman, Praechompoo Pongtornpipat, Winnie S. Liang, Soumya S. Rajan, Amit Dipak Amin
Supplementary References
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dfec1675270c54411c87d5dee629c90
https://doi.org/10.1158/0008-5472.22405217
https://doi.org/10.1158/0008-5472.22405217
Autor:
Jonathan H. Schatz, Soham D. Puvvada, Yves A. Lussier, Lisa M. Rimsza, Jonathan Adkins, Lori Cuyugan, Tara L. Peters, Edgar O. Tapia, Matthew J. Groysman, Praechompoo Pongtornpipat, Winnie S. Liang, Soumya S. Rajan, Amit Dipak Amin
The anaplastic lymphoma kinase (ALK) is chromosomally rearranged in a subset of certain cancers, including 2% to 7% of non–small cell lung cancers (NSCLC) and ∼70% of anaplastic large cell lymphomas (ALCL). The ALK kinase inhibitors crizotinib an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10e62e78d33751d13e5903ebb7cbb2e5
https://doi.org/10.1158/0008-5472.c.6506774
https://doi.org/10.1158/0008-5472.c.6506774
Autor:
Jonathan H. Schatz, Soham D. Puvvada, Yves A. Lussier, Lisa M. Rimsza, Jonathan Adkins, Lori Cuyugan, Tara L. Peters, Edgar O. Tapia, Matthew J. Groysman, Praechompoo Pongtornpipat, Winnie S. Liang, Soumya S. Rajan, Amit Dipak Amin
Supplementary Figure Legend. Legend for Supplementary Figures S1-S5.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7916640597ca9ce10a63c191b5f7fcb0
https://doi.org/10.1158/0008-5472.22405223
https://doi.org/10.1158/0008-5472.22405223
Autor:
Lingxiao Li, Ana A. Tula-Sanchez, Jonathan H. Schatz, Praechompoo Pongtornpipat, Tara L. Peters
Publikováno v:
Oncotarget
// Tara L. Peters 1 , Lingxiao Li 2 , Ana A. Tula-Sanchez 3 , Praechompoo Pongtornpipat 4 , Jonathan H. Schatz 2 1 Sheila and David Fuente Graduate Program in Cancer Biology, Division of Hematology-Oncology, Sylvester Comprehensive Cancer Center, Uni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f23ec2668257745f25a80886e4c70a07
https://doi.org/10.18632/oncotarget.11457
https://doi.org/10.18632/oncotarget.11457
Autor:
Carlos Jiménez-Romero, Gillian Paine-Murrieta, Patricia Greninger, Elizabeth Lemm, Praechompoo Pongtornpipat, Lingxiao Li, Graham Packham, Cyril H. Benes, Abimael D. Rodríguez, Amit Dipak Amin, Luis A. Amador, Joseph Tillotson, Alison Yeomans, Christopher J. Zerio, Sarah Wilmore, Tara L. Peters, Andrew J. Ambrose, Eli Chapman, Francisco Vega, Jonathan H. Schatz
Purpose: The DEAD-box RNA helicase eIF4A1 carries out the key enzymatic step of cap-dependent translation initiation and is a well-established target for cancer therapy, but no drug against it has entered evaluation in patients. We identified and cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1f6f6b9b23765b0975754b23eaefc9b
https://eprints.soton.ac.uk/423285/
https://eprints.soton.ac.uk/423285/